Author
Shoichi Kuyama
Recent research
- Health & MedicineOpen access
Perioperative Durvalumab for Resectable NSCLC : Updated Outcomes for Japanese Patients in AEGEAN
ABSTRACT In the phase 3 AEGEAN study, perioperative durvalumab plus neoadjuvant chemotherapy significantly improved the primary endpoints of event‐free survival (EFS) and pathological complete response (pCR) in patients with resectable NSCLC versus neoadjuvant chemotherapy alone....